Podcasts about Neglected diseases

What do Fareed Zakaria, Nikki Haley, Microsoft CEO Satya Nadella, Google CEO Sundar Pichai, Vinod Khosla and Kamala Harris all have in common? They are all, of course, highly successful Americans of Indian descent. According Meenakshi Ahamed, author of Indian Genius, one reason for what she calls the “meteoric rise” of Indians in America are their humble beginnings here. Arriving with minimal resources (what she calls the "$8 club"), Ahamed attributes their success to "jugaad" (resourcefulness), competitive spirit, family values, and an emphasis on education. She notes Indians are America's fastest-growing immigrant group, with traditionally Democratic voting patterns, though a 10% shift toward Republicans occurred in recent elections. So what are the chances that Trump will read Indian Genius to understand the upside of immigration to America? Less than zero, of course. 5 Key Takeaways * Successful Immigration Counter-Narrative: Ahamed's book presents a counter-narrative to anti-immigrant rhetoric, showcasing how Indian Americans have made significant contributions to American society, particularly in medicine, technology, and business.* The "$8 Club" Phenomenon: Many successful Indian immigrants came to America with extremely limited resources (just $8 due to India's currency restrictions) yet achieved remarkable success through determination, education, and hard work.* "Jugaad" Mindset: Ahamed attributes much of Indian immigrants' success to "jugaad" - a resourcefulness and ability to create something from nothing, developed in India's competitive environment where people must constantly find ways to get ahead.* Generational and Class Dynamics: Earlier Indian immigrants (1965-2010) typically came from upper castes with access to education, though this is changing. Additionally, Ahamed notes differences between first-generation immigrants like Vinod Khosla and later arrivals like Nadella and Pichai.* Shifting Political Allegiances: While Indian Americans traditionally voted 75% Democratic, Ahamed notes a recent 10% shift toward Republicans, particularly among younger Indian American men born in the US, reflecting broader demographic voting patterns.Meenakshi Ahamed was born in 1954 in Calcutta, India. After finishing school in India, she obtained an MA from Johns Hopkins University's School of Advanced International Studies in 1978. She has had a varied career as a journalist, and prior to that, as a development consultant. She has worked at the World Bank in Washington, DC, as well as for the Ashoka Society. In 1989, she moved to London and became the foreign correspondent for New Delhi Television (NDTV). After returning to the United States in 1996, she worked as a freelance journalist. Her op-eds and articles have been published in the Asian Age, Seminar, Foreign Policy, the Wall Street Journal, and the Washington Post. She has served on the board of Doctors Without Borders, the Turquoise Mountain Foundation, and Drugs for Neglected Diseases. She divides her time between the United States and India.Named as one of the "100 most connected men" by GQ magazine, Andrew Keen is amongst the world's best known broadcasters and commentators. In addition to presenting the daily KEEN ON show, he is the host of the long-running How To Fix Democracy interview series. He is also the author of four prescient books about digital technology: CULT OF THE AMATEUR, DIGITAL VERTIGO, THE INTERNET IS NOT THE ANSWER and HOW TO FIX THE FUTURE. Andrew lives in San Francisco, is married to Cassandra Knight, Google's VP of Litigation & Discovery, and has two grown children.Keen On America is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit keenon.substack.com/subscribe

This week on Data in Biotech, we welcome Timothy Jenkins, the Head of Data Science and Associate Professor at DTU Bioengineering, a leading scientific community dedicated to advancing areas of biotechnology, food technology, and health through innovative teaching and research.  Timothy starts the conversation by walking us through his background and early career beginnings, from the first time he expressed interest in zoology and venomous snakes to now leading a research group focused on AI-guided drug discovery for snake antivenom. He and our host, Ross Katz, dive into one of DTU's most exciting recent publications about "de novo" designed proteins to neutralize lethal snake venom toxins.  Inspired by Nobel Prize winner David Baker's groundbreaking paper and in collaboration with the Baker Lab on computational design methodology, this project holds great promise in therapeutic discovery and drug development. Tim explains how computational protein design and protein structure prediction are revolutionizing his field, highlighting compelling examples and milestones from his research on antivenom. He also provides an overview of the process used to discover new antivenoms, including the sourcing of biological data, model training, and integration of experimental feedback. Finally, we get Tim's perspective on the future of AI-powered therapeutic discovery, and his take on the integration of quantum computing into protein design. Data in Biotech is a fortnightly podcast exploring how companies leverage data innovation in the life sciences. Useful Links Nature - De novo designed proteins neutralize lethal snake venom toxins Timothy's LinkedIn DTU Bioengineering Website UW Institute for Protein Design “de novo” designed proteins project Information on Nobel Prize winner David Baker

Now more than ever, it's important to challenge the world's food and beverage manufacturers to address nutrition issues like obesity and undernutrition. Today, we're going to discuss the 2024 Global Access to Nutrition Index, a very important ranking system that evaluates companies on their nutrition related policies, product portfolios, marketing practices, and engagement with stakeholders. The index is an accountability strategy produced by ATNI, the Access to Nutrition Initiative, a global nonprofit foundation seeking to drive market change for nutrition. Our guest today is Greg Garrett, Executive Director of ATNI. Interview Summary You know, I very much admire the work you and your colleagues have done on this index. It fills such an important need in the field and I'm eager to dive in and talk a little bit more about it. So, let's start with this. You know, we've all heard of the concept of social determinants of health and more recently, people have begun talking about corporate determinants of health. And your organization really is focused on corporate determinants of nutrition. Let's start with a question that kind of frames all this. What's the role of industry in nutrition, according to the way you're looking at things? And how does the Global Index shine a light on this topic? Thanks for the question. We're working primarily quite downstream with large manufacturers and retailers. But we hope to affect change across the value chain by working with that group. Of course, when we talk about private sector in food, that's a very, very broad terminology that we're using. It could include farmers on the one hand, looking all the way upstream, all the way through to SMEs, aggregators, processors, manufacturers. SMEs are what? Small and medium enterprises, small and medium enterprises, local ones. All the way through to the multinational food and beverage manufacturers. But also catering organizations and restaurants. When we talk about business what we're trying to do is ensure that business cares about portability, and access to safe and nutritious food. And I think we can say pretty safely, based on the data which we'll talk about, that the health aspects of food are still not as, they're not at the forefront like they should be. Yet. We'll dive in and talk a little bit more about what the index is and what it shows in a minute. But let's start with a kind of broader question. What is the role of diet and consumption of processed foods in influencing health? Yes, so they say now one in five deaths are related to poor diet. It's arguably now the biggest risk factor related to global morbidity and mortality. We've seen in the last 20 years a slight slowing down of our efforts to combat malnutrition and undernutrition. Whereas we've seen over nutrition, obesity, really taking off. And that's not just in high income countries, but also low- and middle-income countries. So, you know, it might be too little good food and that can lead to at the extreme end of things wasting. It might be too little micronutrients, which can lead to all kinds of micronutrient deficiencies or hidden hunger that leads to many adverse outcomes. Including, for example, cognitive decline or reduced immune system. And then, in terms of diabetes and obesity, we're seeing that really skyrocket. Not only in countries where we have excessive food intake, but also in low- and middle-income countries where they have too much food with a lot of, say, empty calories. Not enough nutrients that are needed. In fact, the recent numbers that we've been working with, it looks like in the last 20 years, obesity rates have gone from about 7.9 percent to 15.9 percent. And by 2030, it might be that 20 percent of global population is considered obese if we don't mitigate that. Right, and of course that number is many, many times higher in the developed countries. So, you've got a tough job. You talked about the complexity of the food industry going all the way to the farmers, to the big companies, and caterers even, and things. And a lot of different health outcomes are involved. How in the world do you construct an index from all that? Why don't you tell us what the Global Index is, and then some of what you found in the most recent report. Yes, so the Global Index, we've been running it for 11 years since ATNI was founded. And it has gone through multiple iterations. This latest one was the biggest we've done and we tried to capture about a quarter of the world's market. So, what we did is we took the 30 largest food and beverage manufacturers by revenue. We looked at 52,000 of their products, and that's where we know the market share was about 23 percent global market share. We profiled the foods. We tried to understand their governance structures and how much nutrition features in the way they run their business. We tried to understand, for example, how they market the foods. Are they marketing them responsibly, according to the World Health Organization guidelines? Really dive deep. It's dozens and dozens of indicators where we ask lots of questions of the companies over a 10-month period. And, by doing that, we hope to understand how financially material is nutrition to these companies. We want to give something of use, not only for the companies, but to policymakers. Because we know there's a big role for policymakers to both incentivize the production and the marketing of healthy foods, but also disincentivize unhealthy foods. We want this to be useful for investors. So, we spend a lot of time, through collaborative engagements, working with the shareholders of these companies as well so that they can invest more responsibly in the food company. And then the other group that we hope to eventually work with are the consumer associations. The groups that would represent consumers so that they can put appropriate pressure on the demand side, you know. They can demand healthier food. It's not that we believe by running an index somehow companies are going to start doing everything right. No. We want to provide data and analysis to the sector so that all the stakeholders can use it to help influence change. That makes perfect sense to have some data driven enterprise to figure out what's actually going on. Otherwise, you're just having to go on intuition. So, what did the most recent index find? Right, so out of those 30 companies, what did we find? There's some good news. Let's start with the good news before we get into the bad news. There's maybe more bad news than good news. In aggregate, we're actually now seeing that 34 percent of the revenue derived from the products that we profiled, those 52,000 products, is based on healthier sales. Meaning 34 percent could be considered healthier foods. That doesn't sound great, maybe, but consider just 4 years ago when we ran this index, it was at 27%. So, there's some marginal increase and maybe if we can accelerate things, and that's what we're trying to do, it's our big strategic objective. We hope that by 2030, we could say that at least half of business' revenue is coming from healthier food options. There's a lot of changes that need to take place to get to that point, but some companies are doing it. Also, we noticed a lot more companies are now starting to use a government endorsed nutrient profile model to define the healthiness of the food products, to measure and monitor the healthiness of their food portfolios, and then to disclose that. That's really good. It's the beginning. First step is measure, disclose. The second step would be put targets on that and actually start to get substantive change towards 2030. But there was a lot of unfortunate news too. We had some backsliding from some of the major companies. For example, low- and middle-income countries actually had the lowest health score. What we think is happening, based on the data we looked at, is that if you're a low-income country, you're getting the lowest healthiness score of these products in your country. So, brand X would be slightly healthier in Europe, but less healthy in the low-income country. So there's a need for regulation there. Can I stop and ask you a question about that? I've got a million questions just flying out of my head that I'm dying to ask. But what you reminded me of is the history of the tobacco industry. When the policies came into play, like very high taxes and banning smoking in public places in the developed countries, US specifically, the smoking rates went way down. But the companies made more money than ever because they just went outside the US. Especially the developing countries and were selling their products. So, it sounds like the food companies might be engaged in a similar enterprise. But why in these countries would they be pushing their least healthy foods so aggressively? I'll start with the facts, because there's some speculation here. But the fact is, if you look at your own monitored data, the highest growth of the modern food retailers is in Africa. So, you've got, for example, 80 to 300 percent growth over the last 5 years in Africa of these modern food retail shops. And in Asia, that's, that's already happened. Still happening in some countries. So, you have enormous opportunity for packaged foods, right? Because that's usually what they're selling, these retailers. I think you have some aspiration going on there, too. I think there's consumers who aspire to have convenient foods. They're more affordable now as incomes increase in those settings. Now, regulation is definitely, in general, in those countries, not as mature as it might be in Europe when it comes to colorants, and taxing, say, sugar sweet beverages. So, what you've asked, I think there's some truth to it. I don't want to come out and say that that's exactly what's happening, but we ran the numbers and the healthiness score. So, we use a five-star rating system. The Health Star rating system, one to five. Anything 3.5 or above, we would consider healthier in a diet. 3.4 and below would be considered unhealthy. And the score in low-income countries was 1.8. And in middle to high income, it was 2.4. So, it's quite a, quite a big difference. That's really very striking. You know, I guess if I'm a food company and I just want to maximize my profits, which of course companies are in business to do, then what I'm going to sell are the foods that people eat the most of. Those are the ones that are triggering the brain biology, the 'over consume'. And the ones that have the greatest shelf life and are easiest to produce and things like that. So, I'm going to make processed foods and push those into new markets as aggressively as I can. So, I'm not asking you to think through the corporate mindset about what's driving this. But it sounds like the data that you have, the end product of all these practices, would be consistent with thinking like that. We like to think that there could be a role for healthier processed foods. But it has to be in moderation. So, what we looked at is the materiality of nutrition. Are companies actually able to have their business and have a healthier food portfolio? So, before we ran the global index, we did an assessment of this. And what we found is that if you're a mixed food company, and you decide to reformulate so that over time you have a healthier food portfolio, in fact, we found that their capital valuations and how they did on the market was slightly better. Not a lot. Than their say, less healthy counterparts. So, what we see is the beginning of a 'health is wealth' sort of narrative. And we hope that we can drive that forward. And of course, policy would help a lot. If policy would come out and say, let's tax the bad, subsidize the good. Then I think industry is going to fall in line. So, we're not sympathetic with industry because a lot of what's happening is not good. On the other hand, we're realists. And we know that these companies are not going away. And we need to make sure that what they offer is as healthy as it should be. And there's a role for everybody in that. All right, that's such an interesting perspective. So, you talked about the global findings. What can you say about the US in particular? What I'd like to do is actually refer to our 2022 US index. So, we did a deep dive just recently; October 2022, right after Biden's Nutrition Conference in DC. And, it wasn't really positive in the sense that we looked at 11 companies. The 11 biggest companies representing 170 billion revenues in the US. And 30 percent of all US food and beverage sales were based on healthier food options. Now, that was 4 years after we ran a 2018 US index. So, 2018, same thing, 30%. There's no change. It's still as unhealthy as ever. I think we need the US to come on board here because it is such a leader. A lot of these companies are headquartered in the US. So, we need to see that healthiness score go up in the US. You know, it's interesting some of the things you mentioned companies might be doing outside the US would be helpful if they did take place in the US. Like front of package labeling would be one example of that. So that would be a place where American companies are behind the curve, and it would be helpful if they caught up. It'd be interesting to dissect the reasons for why they are. But it's interesting that they are. What are some of the things businesses are doing to improve nutrition outcomes? Let's talk maybe on the more positive side. Do you think there's progress overall? It sounds like it from the numbers that you're presenting. But are there signs also of backsliding? And what do you think some of the successes have been? Yes, and I think we can get specific on a few. There's a company headquartered in Mexico, Grupo Bimbo. They rose up in the rankings six places between our 2021 Global Index and this one in 2024. They've been reformulating. They've been making their product portfolio healthier overall. It's about 50 percent now. I think some of that was their own initiative, but it was also prompted by a lot of Latin America's regulations, which is great. I think we can learn a lot from Latin America when it comes to front of pack labels and taxes. So, Group of Bimbo was a good success story. Arla, a Danish dairy company, they came out on top in the index in terms of marketing. So, they have basically said they're not going to market unhealthy foods to children under the age of 16. And they try to even go to 18, but it isn't quite being monitored across all digital platforms. And that's the next level is to take it to the digital platforms and monitor that. And that was a bit disappointing in general, just to find that out of the 30 companies, not one is able to come out and say that they followed the WHO Guidelines on Responsible Marketing 100 percent. The latest index shows that nine out of the 30 companies now, or 30%, nine out of the 30 companies are now using a government endorsed nutrient profile model to define healthy, and then monitor that across their portfolios. And that's a lot of progress. There were only a handful doing that just four years ago. We would ask that all 30 use an NPM, a nutrient profile model, but nine is getting somewhere. So, we're seeing some progress. Boy, if not a single company met the WHO Guidelines for Food Marketing it shows how tenacious those practices are. And how important they are to the company's bottom line to be able to protect that right to market to kids, vulnerable populations, to everybody really. So it really speaks to keeping that topic in the limelight because it's so important. We'd like investors to come out and say they will only invest in companies that are moving towards a 2030 target of marketing response. Zeroing in on 1) responsible marketing and 2) the healthiness food product. Zero in on those two things make really clear what the metrics are to measure that. So, you've mentioned several times, a very important, potentially very important group: shareholders. And you said that that's one of the stakeholders that you interact with. Are there signs out there of activist stakeholders? Shareholders that are putting pressure on the companies to change the way they do business. Yes. So, institutional investors have the ability to talk directly to the board, right? And they have the power in many cases to remove the CEO. So, they're a powerful group, obviously, and we've worked with over 80 now. And had them work with us to understand what investing in a progressive food company would look like. It's making better and better decisions, continuous improvements on nutrition. We have 87, I think is the latest count, who have signed a declaration to invest like this in a food healthier business. They represent $21 trillion of assets under management. It's a very powerful group. Now are all 80 actively, like you mentioned activist shareholders, you know, pushing, say, for example, for resolution. No. Some are. And they're using our data for that. And we applaud any kind of action towards better nutrition, healthier foods, better marketing using our data. We, as ATNI, do not sign these shareholder resolutions. But we absolutely will make our data available as a public good so that they can be used by this powerful group to yeah, hold the companies to account and hopefully invest in the long term. That's what it comes down to. Because it's true that this will take time for the benefits to come to both business and to people, but it's worth it. And I think the longer-term investors get it. And that's why they're doing these shareholder resolutions and different other investor escalation strategy. That strikes me as being pretty good news. Let's go down this road just a little bit further, talking about this, the shareholders. So, if the shareholders are starting to put, some at least, are putting pressure on the companies to go in a healthier direction, what do you think is motivating that? Do they see some big risk thing down the road that they're trying to anticipate and avoid? Is it policies that if the companies don't behave, governments might feel more emboldened to enact? Is it litigation that they see? What are they trying to avoid that's making them put pressure on the companies to move in these directions? That's a great question. When we ran the materiality assessment on nutrition earlier this year, we interviewed many of the investors and it seemed to come down to three things. One, there is coming regulation. There's more and more evidence that when you regulate the food system and you regulate food industry, and you do it in a smart way through a two-tiered levy system, for example, on sugar sweetened beverages. You tax the company, not the consumer. It actually does work. You have a decrease in consumption of these beverages. So coming regulation. The other one is increasing consumer demand for healthier options. Now, that might not be happening yet everywhere. And I think it only really happens when people can afford to demand healthier foods, right? But it seems like it's a trend everywhere as incomes increase and people's knowledge and understanding of nutrition increases, they do want healthier options. So, I think investors see that coming. And the third one is healthcare bills. Now, the investors don't always pick that up. Although in the case of some of our insurance companies who we work with, like AXA, it does. But they see the big macroeconomic picture. And we were talking to one of the investors last week, and they said it's all about megatrends. For them it's about investing in the megatrends, and they see this as a mega trend. This, you know, growing obesity, the cost related to obesity, growing costs related to diabetes and all NCDs. And they don't want to be investing in that future. We need to be investing in a healthier future. I think those are the three things we're gathering from the investors. So, Greg, there's sort of this jarring reality, it seems to me. And other people have written about this as well. That if the world becomes healthier with respect to its diet; let's just say you could wave a magic wand and obesity would go from its very high levels now to much lower levels or even zero. It means the world would be having to eat less food and the companies would be selling less food. And then you superimpose upon that another jarring reality that people simply buy more, eat more, of less healthy options. So, if a child sits down in front of a bowl of plain cornflakes, they're going to eat X amount. If that's sugar frosted flakes, they're going to eat, you know, 1.5 X or 2 X or whatever the number is. So, how can the companies try to make as much money as possible and be true to its shareholders and shareholders while at the same time, facing these realities. That's a great question. It goes to the heart of what we're trying to do at ATNI. That's why we say we're transforming markets for nutrition. Because if we don't help support that underlying market change, then we won't get very far in a sustainable way. You mentioned calories and over consumption. And that, of course, is part of the problem, but I think it's equally fair to say not all calories are treated the same and we need to look at the ingredients going into these food products to begin with. You know, why is sugar or any kind of corn derivative such an attractive cheap ingredient to put into food? And so bad for people if it's not eaten with anything else, if it's just an empty carb, for example. It's because of the subsidies, the billions of dollars of subsidies going into sugar around the world. In the United States, a very large subsidy going to the corn industry. And so, corn is then turned into many types of derivatives, many different types of ingredients that go into our foods. So, that's one thing. I think the other is that there's a big role for food policy to level the playing field. We hear this all the time from our industry partners, and we tend to agree. You know if two or three of the 30 companies that we just indexed stick their neck out and do something good, it'll work for two or three years until the other 27 start to undercut them. And if they're somehow making, you know, better money, bigger profits, more market share it's going to be very tempting for the three that made the good decisions to go back to what they were doing before. We have to change the market structure and end the perverse market incentives. Makes sense. One final question. What can policymakers do? I think we've touched on it a little bit. There's the fiscal policy space, which we're very excited about at ATNI. There are over 100 jurisdictions now that have put in place some kind of sugar sweetened beverage tax. But why not expand that take it to any kind of product which is too high in sugar, right? And again, make it like a proper levy on the company and not the consumer. Because that's where the evidence is that it works. Subsidies, you know, there's very few countries which are subsidizing healthier foods. Instead, you're seeing subsidies, as we just mentioned, going to the wrong kind of product. So that's one. And here's a new one: environmental, social, and governance investing metrics. As countries start to mandate the disclosure requirements for publicly listed companies, why not include two nutrition metrics? One on marketing, one on healthiness, so that every food company is mandated to disclose information on these things. That would be a real innovative way for policymakers to help regulate things. And front of pack labeling. You mentioned it yourself earlier. We would agree clear front of pack labels. So, the consumers know what's healthy and what's not. BIO Greg S Garrett is the Executive Director of ATNI (Access to Nutrition Initiative), a global foundation supporting market change for nutrition. Greg has held several leadership roles over the past twenty years, including serving on the Global Executive Team of the Drugs for Neglected Diseases initiative (DNDi), directing Abt Global's health reform in Kyrgyzstan and leading strategy at ThinkWell, a global health organization. During his eight years with the Global Alliance for Improved Nutrition (GAIN), Greg served as Director of Food Fortification and Director of Policy & Financing during which time he established a multi-million-dollar financing facility and managed a portfolio that reached one billion people with fortified foods. Greg serves on the Global Nutrition Report's Stakeholder Group and is a member of the Blended Finance TaskForce. He holds a BA and an MSc in International Development from the University of Bath, UK.

The Bill & Melinda Gates Medical Research Institute (Gates MRI) is a non-profit medical research organization dedicated to the development and effective use of products like drugs, vaccines and monoclonal antibodies to address substantial global health concerns, for which investment incentives are limited, including malaria, tuberculosis, diarrheal diseases, and diseases that impact maternal, newborn, and child health.This week, our guest is Dr Claire Wagner, head of corporate strategy and market access at Gates MRI.Wagner has dedicated her life to global health. Her early years working in West Africa and East Africa – including five years working with the Rwanda Ministry of Health – were formative experiences for her. She helped document health sector outcomes in Rwanda and had a front row seat to the progress the country was making at the time, which led to her pursuing and obtaining an MD and MBA from Harvard.Her experiences led to her becoming one of the early employees of the Gates MRI, where she is on the executive leadership team and leads the institute's global access strategy as well as related engagement with commercial partners, financial institutions and multilaterals.She tackles the challenge of paving the way for the drugs, biologics and vaccines that the Gates MRI is developing – if they are successful in clinical trials – to be affordable and accessible to the people in low- and middle-income countries who would benefit most. In March 2024 the Gates MRI launched a phase 3 clinical trial for a tuberculosis vaccine candidate, and market access for this candidate is a top priority for Wagner.01:51-04:47: Background on Dr Claire Wagner04:47-06:24: Work in Rwanda06:24-08:40: Gates MRI08:40-12:50: Progress at Gates MRI12:50-14:06: Gates MRI R&D priorities14:06-16:26: The differences between Gates MRI and traditional biotechs16:26-18:40: Gates MRI partnerships18:40-22:52: The inequality of developing drug treatments22:52-25:45: Return on investment25:45-27:01: Did COVID increase global awareness?27:01-27:44: Other companies working on treatments27:44-31:48: Gates MRI pipeline and clinical trials31:48-34:51: Working on tuberculosis34:51-36:00: Treatment mode of action36:00-37:25: Future work at Gates MRIInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

Send us a Text Message.On Inside Geneva, we bring you part three of our summer profile series. This week we talk to a doctor looking for treatments for some of the world's most neglected diseases.“Neglect means that there are diseases that affect an important proportion of humanity but for which no new drugs have been developed because there is no money in it. Because they affect very poor populations in remote rural areas,” explains Olaf Valverde, clinical project leader at Drugs for Neglected Diseases (DNDi).Valverde is the clinical lead on a project looking for treatments for sleeping sickness.“It's a disease caused by a small parasite that almost always kills if untreated. During the first half of the 20th century there were huge epidemics. It not only destroyed communities but also caused the desertification of entire regions of Africa,” he adds.Cases of sleeping sickness with no effective treatment had been rising again until DNDi began combing medical trials – some abandoned by big drug companies as not profitable – for other options. They found one promising lead and began testing in the Democratic Republic of Congo (DRC).“The motivation, concentration and interest shown by our doctors in the DRC who were developing the clinical trial, were totally amazing. For them it was an opportunity to serve their people. And that was absolutely beautiful,” says Valverde.The drug worked and sleeping sickness is on the way to being eradicated.“I think this is what I always wanted to do; to do something that could be helpful to others. And this is what satisfies me. Just seeing that people have opportunities.”Join host Imogen Foulkes on Inside Geneva to listen to the full interview. Please listen and subscribe to our science podcast -- the Swiss Connection. Get in touch! Email us at insidegeneva@swissinfo.ch Twitter: @ImogenFoulkes and @swissinfo_en Thank you for listening! If you like what we do, please leave a review or subscribe to our newsletter. For more stories on the international Geneva please visit www.swissinfo.ch/Host: Imogen FoulkesProduction assitant: Claire-Marie GermainDistribution: Sara PasinoMarketing: Xin Zhang

We kick off season 4 of the Global Health Matters podcast with an episode that highlights the remarkable career journeys of two research leaders and the role of capacity development in their formation. Host Garry Aslanyan speaks with Wilfried Mutombo, the Head of Clinical Operations at the Drugs for Neglected Diseases initiative (DNDi) in the Democratic Republic of the Congo, as well as Yasmine Belkaid, President of the Institut Pasteur in France. As this episode is produced in celebration of the 50th anniversary of TDR, the Special Programme for Research and Training in Tropical Diseases, TDR Director John Reeder also joins this episode to reflect on the challenges and future frontiers of capacity development.Related episode documents, transcripts and other information can be found on our website.Subscribe to the Global Health Matters podcast newsletter.  Follow @TDRnews on Twitter, TDR on LinkedIn and @ghm_podcast on Instagram for updates.  Disclaimer: The views, information, or opinions expressed during the Global Health Matters podcast series are solely those of the individuals involved and do not necessarily represent those of TDR or the World Health Organization.  All content © 2024 Global Health Matters. 

Are you tired of seeing the world struggle with global health crises? It's a harsh reality that many vaccine-preventable diseases continue to devastate vulnerable populations. But there's hope on the horizon!In this eye-opening episode, we dive deep into a conversation with Colin McCann, a key player at the International Vaccine Institute (IVI), who shares incredible insights into their innovative approach to combatting these health challenges. You'll discover the groundbreaking strategies and collaborative efforts reshaping how we develop and deliver life-saving vaccines to those who need them most.Don't miss out on this unique opportunity to learn about the future of global health and how the IVI is making a real difference. Click now to watch the full episode and get inspired!

Mark interviews Dr. Lisa Jones-Engel from PETA.Is this how the next pandemic begins? Tens of thousands of monkeys are imported into the US every year to be mutilated, poisoned, deprived of food and water infected with painful and deadly diseases and eventually killed in laboratories! Does it do any good for humanity? Or is it just a big greedy business?Dr. Lisa Jones-Engel is a senior science advisor on primate experimentation for People for the Ethical Treatment of Animals (PETA). A Fulbright scholar who has studied the human-primate interface in Africa, Asia, and the primate biomedical facilities of the U.S. for nearly 40 years, she has published 95 peer-reviewed articles spanning the fields of primatology, virology, epidemiology, microbiology, and conservation. Her most recent book, Neglected Diseases in Monkeys From the Monkey-Human Interface to One Health, was published in 2020. Her work includes addressing the neglect and disease risk posed by the University of Washington's Washington National Primate Research Center, where she worked before coming to PETA.

Mark interviews Dr. Lisa Jones-Engel from PETA.Is this how the next pandemic begins? Tens of thousands of monkeys are imported into the US every year to be mutilated, poisoned, deprived of food and water infected with painful and deadly diseases and eventually killed in laboratories! Does it do any good for humanity? Or is it just a big greedy business?Dr. Lisa Jones-Engel is a senior science advisor on primate experimentation for People for the Ethical Treatment of Animals (PETA). A Fulbright scholar who has studied the human-primate interface in Africa, Asia, and the primate biomedical facilities of the U.S. for nearly 40 years, she has published 95 peer-reviewed articles spanning the fields of primatology, virology, epidemiology, microbiology, and conservation. Her most recent book, Neglected Diseases in Monkeys From the Monkey-Human Interface to One Health, was published in 2020. Her work includes addressing the neglect and disease risk posed by the University of Washington's Washington National Primate Research Center, where she worked before coming to PETA.

Notable gaps exist when it comes to knowledge and diagnosis of several diseases affecting companion animals, especially canines. Rhoel Dinglasan Ph.D, a vector-borne disease expert, discusses a selection of these diseases, and how current research aims to close those gaps.

The India-US relationship is one of the most significant and fascinating among great nations. In this episode of the Serve to Lead Podcast, historian and journalist Meenakshi Ahamed discusses her new book, A Matter of Trust: India-US Relations From Truman to Trump. Ahamed combines analytical rigor with a storyteller’s gift for narrative. The book has garnered critical acclaim, and is a finalist for the prestigious Arthur Ross Award of the Council on Foreign Relations.Seventy years of India-US relations has shown that despite the two countries being democracies, not only are they far apart culturally but the intersection of their critical interests is relatively modest. Therefore, the only time when the relationship has developed any real momentum is when one of the leaders has been willing to make a leap of faith.—Meenakshi AhamedIndia’s world role continues to evolve amid the kaleidoscopic changes underway with the rise of China and other challenges to the so-called liberal international order that has prevailed since the end of the Second World War. Ahamed illuminates current issues—such as India’s decision not to join the United States in support Ukraine’s struggle against Russian aggression in 2022—through her understanding of India’s history of non-alignment during the twentieth-century Cold War. She also has a keen understanding of the unique contributions of Indian-Americans in US business, which may continue to pull our nations ever closer in the decades ahead.Critical Acclaim'Meenakshi Ahamed has brought us a brilliant, important, sparkling and definitive study of a part of American history that is growing more crucial by the day. A Matter of Trust is essential reading at a moment when the United States and India are all the more central to each other, and when valiant democracies around the world are in danger.'—Michael Beschloss, New York Times bestselling author and NBC News Presidential Historian'Meenakshi Ahamed has given us an authentic, thoughtful and accessible account of a relationship characterized by paradox and progress. She tells the tale of the highs and lows of that relationship in all its drama, with strong and idiosyncratic personalities on both sides. Today's transformed India-US relations could determine the future not only of one-fifth of humanity but of the Asian Century. This is a book with a serious message—one to read and savor.'—Shivshankar Menon, Former National Security Advisor, Ambassador to China and Foreign Secretary'In this world of growing great power competition, the Indian-American relationship has become one of central, strategic importance to the two nations. In her history of the relationship, Meena Ahamed has given us a timely, lively and captivating account of the road India and the United States have travelled and a compelling insight into what lies ahead.'—Frank G. Wisner, Former United States Ambassador to India'Meenakshi Ahamed's labor of love is a real tour de force covering the long tortuous history of the often-troubled relationship of the world's two largest democracies since India's independence. The book is at once scholarly, deeply researched and yet down to earth. It brings to life the prickly personalities on both sides, and their sensitivities, that often bedeviled the evolving bilateral relationship. As a new era of competitive geopolitics pits West versus East, what lies ahead for this unusual relationship? To prepare ourselves this book is a must-read.'—Dr Rakesh Mohan, Former Deputy Governor Reserve Bank of IndiaAbout the AuthorMeenakshi Narula Ahamed was born in 1954 in Calcutta, India. After finishing school in India, she obtained an MA from Johns Hopkins University’s School of Advanced International Studies in 1978. She has had a varied career as a journalist and prior to that as a development consultant. She has worked at the World Bank in Washington D.C. as well as for the Ashoka Society. In 1989, she moved to London and became the foreign correspondent for NDTV. Among the leaders she interviewed were Nelson Mandela, John Major and Bill Clinton during his presidential campaign. She covered the race riots in London and reported on the rise of Indian entrepreneurs in the US in the mid nineties. After returning to the US in 1996, she worked as a freelance journalist. Her op-eds and articles have been published in Asian Age, Seminar, Foreign Policy, Wall Street Journal and the Washington Post. She has served on the board of Doctors Without Borders, The Turquoise Mountain Foundation and Drugs for Neglected Diseases. She divides her time between the US and India.The Serve to Lead podcast has recently moved to Substack (and continues to repopulate in updated settings). It can be accessed in the usual formats, including:Apple Podcasts | Amazon Audible | Amazon Music | Google Podcasts | iHeart | Spotify | Stitcher | Podchaser | TuneIn Image credit: HarperCollins Publishers. Get full access to The Next Nationalism at jamesstrock.substack.com/subscribe

Our episode last week ended on a hopeful note, a rare occurrence for this podcast, and it was due in large part to the incredible decline in reported cases of human African trypanosomiasis (HAT) over the past decade. In this bonus episode, we explore one of the major reasons behind this drop in HAT: the new medication fexinidazole, developed through a partnership between the Drugs for Neglected Diseases initiative (DNDi), a non-profit organization dedicated to developing new treatments for neglected diseases and Sanofi, a French healthcare company. We are thrilled to be joined by two researchers from DNDi, Dr. Nathalie Strub-Wourgaft and Dr. Wilfried Mutombo Kalonji, who share their insights into the challenges associated with bringing a medication all the way from its development stage, to testing it in the field, and finally ensuring that access is provided for those who need it most. We also chat about how this treatment works, the impact that COVID-19 has had on screening efforts for sleeping sickness, the lessons learned from fexinidazole's development, and so much more. Tune in wherever you get your podcasts! And when you're finished with the ep, check out this beautiful video from DNDi chronicling the story of fexinidazole: A doctor's dream: A pill for sleeping sickness. See omnystudio.com/listener for privacy information.

In this edition: How the Kigali declaration is hoped to speed up the fight against neglected tropical diseases that affect 20 percent of the world's population and: While they promise jobs, international projects in Mexico often divide communities.

In December 2019, DeepMind's AI system, AlphaFold, solved a 50-year-old grand challenge in biology, known as the protein-folding problem. A headline in the journal Nature read, “It will change everything” and the President of the UK's Royal Society called it a “stunning advance [that arrived] decades before many in the field would have predicted”. In this episode, Hannah uncovers the inside story of AlphaFold from the people who made it happen and finds out how it could help transform the future of healthcare and medicine.For questions or feedback on the series, message us on Twitter @DeepMind or email podcast@deepmind.com. Interviewees: DeepMind's Demis Hassabis, John Jumper, Kathryn Tunyasunakool and Sasha Brown; Charles Mowbray and Monique Wasuna of the Drugs for Neglected Diseases initiative (DNDi]) & John McGeehan of the Centre for Enzyme Innovation at the University of Portsmouth CreditsPresenter: Hannah FrySeries Producer: Dan HardoonProduction support: Jill AchinekuSounds design: Emma BarnabyMusic composition: Eleni ShawSound Engineer: Nigel AppletonEditor: David PrestCommissioned by DeepMind Thank you to everyone who made this season possible!  Further reading: AlphaFold blog, DeepMind: https://deepmind.com/blog/article/alphafold-a-solution-to-a-50-year-old-grand-challenge-in-biologyAlphaFold case study, DeepMind: https://deepmind.com/research/case-studies/alphafoldIt will change everything, Nature: https://www.nature.com/articles/d41586-020-03348-4AlphaFold Is The Most Important Achievement In AI—Ever, Forbes: https://www.forbes.com/sites/robtoews/2021/10/03/alphafold-is-the-most-important-achievement-in-ai-ever/?sh=359278426e0aBacteria found to eat PET plastics, NewScientist: https://www.newscientist.com/article/2080279-bacteria-found-to-eat-pet-plastics-could-help-do-the-recycling/Protein Structure Prediction Center: https://predictioncenter.org/An interview with Professor John McGeehan, BBSRC: https://bbsrc.ukri.org/news/features/enzyme-science/an-interview-with-professor-john-mcgeehan/John McGeehan profile, University of Portsmouth: https://researchportal.port.ac.uk/en/persons/john-mcgeehanDrugs for Neglected Diseases initiative (DNDi): https://dndi.org/A doctor's dream, DNDi: https://www.youtube.com/watch?v=Tk31iucWYdEThe Curious Cases of Rutherford and Fry, BBC: https://www.bbc.co.uk/programmes/b07dx75g/episodes/downloadsHannah Fry: https://hannahfry.co.uk/

Covid-19 has dominated our lives for almost two years. Vaccines have been developed in record time, yet nearly half the world's population has not received a single dose. What has gone wrong?Imogen Foulkes is joined in this podcast episode by global health and policy experts.“How do you solve this in the longer term? You don't want to be in this situation when this happens again. This could happen next month, if the wrong variant comes out,” says Bruce Aylward, senior advisor to the director-general at the World Health Organization (WHO).The new Omicron Covid variant now threatens to undo earlier progress. Do we need a global pandemic treaty?“We have not managed to ensure equitable access. We have left decisions to narrow national interests and to commercial decision-making,” says Michelle Childs, head of policy and advocacy at the Drugs for Neglected Diseases initiative (DNDi). “We need to be optimistic. We must be optimistic. It's in everyone's interest to get out of this pandemic,” says Federica Zamatto, a medical coordinator at Médecins Sans Frontières (MSF).

In this recently recorded live web event, we explore what private strategies ideas can be adopted by the global health community to develop, distribute, and market products for those most in need in low and middle income countries. With the Bay Area Global Health Alliance, Medicines 360, PSI and Resonance. Joining Ben are:Andrée Sosler, Senior Director, Impact and Global Access, Medicines360Margot Fahnestock, Vice President, Strategic Development, Medicines360Brandon Soloski, Senior Manager, Strategic Partnership, PSIMarissa Gilman, Global Health Practice Lead, ResonanceMedicines360 is a nonprofit organization that operates as a pharmaceutical company, which is an exciting innovation for addressing gaps in public health and also poses some challenges and has limitations.Population Services International (PSI) has used marketing and communications techniques to promote better health for decades; a model that has been successfully scaled and replicated and also faces barriers when applied to public health.Resonance is a global consulting firm that delivers market-based solutions to address the world's toughest challenges and is the creator of the Inclusive Innovation Exchange, focused on the innovation process for those designing with emerging markets in mind.www.bayareaglobalhealth.orgwww.medicines360.orgwww.psi.orgwww.resonanceglobal.org#globalhealth #neglecteddiseases #infectiousdisease #publicprivatepartnerships #COVID19 #womenshealth #socialmedia

Original broadcast: 4/24/2018. In the United States we are familiar with common illnesses like the cold and flu, but we only hear about many diseases from beyond our shores, like the Ebola virus, when a case unexpectedly appears here. How can we create drugs to cure these illnesses, which often affect the poorest countries first, […]

0:08 – Anti-black racism in China is forcing people from their homes, jobs, and sense of home Roberto Castillo (@castillorocas) is Assistant Professor with the Cultural Studies Department at the Lingnan University in Hong Kong, and contributor to Quartz.  0:34 – Serology testing and community spread: what's the latest Julia Schaletzky, PhD is Executive Director at the UC Berkeley Center for Emerging and Neglected Diseases. 1:08 – Where Alameda County is finding COVID cases: predominantly POC neighborhoods, East Oakland and Hayward Erin M. Kerrison, PhD (@emkerrison) is assistant professor of social welfare at UC Berkeley. Her research focuses on how law and legal institutions operate as social determinants of health.  You can find the Alameda County data map of COVID cases here.  1:25 – Black Oakland demands to address COVID-19 Cat Brooks puts on her organizer hat and discusses the list of demands to address COVID-19, centering the black community. Here are the demands of the Black New Deal.  1:34 – Americans are stockpiling guns and ammo: what are the responsibilities of individuals and governments to protect public safety David Chipman (@davidchipman) is senior policy advisor with the Giffords Law Center to Prevent Gun Violence.  1:50 – Poetry flash: ‘Open Arms' by devorah major devorah major served as San Francisco's Third Poet Laureate.  She has five poetry books, two novels, four chapbooks, and a host of short stories, essays, and poems in anthologies and periodicals. Major performs her work nationally and internationally with and without musicians – you can find her work at www.devorahmajor.com The post Alameda County: How COVID is impacting the black community the hardest and why; Plus: The latest science on antibody testing appeared first on KPFA.

Dr. Julia Schaletzky explains what it takes to develop vaccines for viruses like COVID-19. Dr. Schaletzky is the Executive Director of the Center for Emerging and Neglected Diseases, the Drug Discovery Center, and the Immunotherapy and Vaccine Research Institute at UC Berkeley. In this special coronavirus coverage from Curiosity Daily, Dr. Schaletzky discusses: What science needs to be done in order to make a new vaccine a reality? Why can’t we grow a live virus vaccine for COVID-19? What are the challenges associated with animal testing? How long does it take to complete clinical trials and why are they so important? What are the differences between ebola vaccine development and coronavirus vaccine development? Why do we update vaccines for the seasonal flu, and will we have to update a COVID-19 vaccine after it’s been developed? What zoonotic viruses have we identified besides COVID-19 and how can we protect humans from them in the future? What is it about a bat’s immune system that increases risk of virus transmission to humans? How long should it take to create a vaccine, and will it happen before we’ve developed herd immunity? What’s the difference between a live virus vaccine, a recombinant vaccine, and an mRNA vaccine, and which might be most effective against coronavirus? How long does it take to be sure a vaccine is safe for humans? Why can’t everyone in the US get a serological test to see if they’ve already had COVID-19? What can the coronavirus pandemic teach us about policies and funding that impacts scientific research in the future? Additional resources from Dr. Julia Schaletzky, Executive Director of the Henry Wheeler Center for Emerging and Neglected Diseases at University of California, Berkeley: Center for Emerging and Neglected Diseases (CEND) http://cend.globalhealth.berkeley.edu/ CEND COVID-19 Outbreak Watch http://cend.globalhealth.berkeley.edu/coronavirus-outbreak-watch/ Immunotherapy and Vaccine Research Institute (IVRI) https://ivri.berkeley.edu/ Department of Molecular & Cell Biology (MCB) faculty bio for Julia Schaletzky, PhD https://haas.berkeley.edu/biology-business/academics/faculty/ Follow @CENDUCBerkeley on Twitter https://twitter.com/CENDUCBerkeley Follow  Dr. Schaletzky’s CEND profile http://cend.globalhealth.berkeley.edu/julia-schaletzky-phd/ Subscribe to Curiosity Daily to learn something new every day with Cody Gough and Ashley Hamer. You can also listen to our podcast as part of your Alexa Flash Briefing; Amazon smart speakers users, click/tap “enable” here: https://curiosity.im/podcast-flash-briefing

Dr. Julia Schaletzky explains why the U.S. is having a hard time testing everyone for the coronavirus. Plus: learn about how ketamine can help with depression and anxiety; and how an anonymous Anime fan on 4chan helped solve a 25-year-old math puzzle. Additional resources from Dr. Julia Schaletzky, Executive Director of the Henry Wheeler Center for Emerging and Neglected Diseases at University of California, Berkeley: Center for Emerging and Neglected Diseases (CEND) http://cend.globalhealth.berkeley.edu/ CEND COVID-19 Outbreak Watch http://cend.globalhealth.berkeley.edu/coronavirus-outbreak-watch/ Immunotherapy and Vaccine Research Institute (IVRI) https://ivri.berkeley.edu/ Department of Molecular & Cell Biology (MCB) faculty bio for Julia Schaletzky, PhD https://haas.berkeley.edu/biology-business/academics/faculty/ Follow @CENDUCBerkeley on Twitter https://twitter.com/CENDUCBerkeley Follow  Dr. Schaletzky’s CEND profile http://cend.globalhealth.berkeley.edu/julia-schaletzky-phd/ How can ketamine treat anxiety? by Ashley Hamer (Listener question from Brock in Utah) Chen, J. (2019, March 21). How New Ketamine Drug Helps with Depression. Yale Medicine; YaleMedicine.org. https://www.yalemedicine.org/stories/ketamine-depression/   Meisner, R. C. (2019, May 22). Ketamine for major depression: New tool, new questions - Harvard Health Blog. Harvard Health Blog. https://www.health.harvard.edu/blog/ketamine-for-major-depression-new-tool-new-questions-2019052216673   U.S. Department of Justice Drug Enforcement Administration (2017). Ketamine. In Drugs of Abuse: A DEA Resource Guide. (pp. 68.) https://www.dea.gov/sites/default/files/sites/getsmartaboutdrugs.com/files/publications/DoA_2017Ed_Updated_6.16.17.pdf#page=68  Gao, M., Rejaei, D., & Liu, H. (2016). Ketamine use in current clinical practice. Acta Pharmacologica Sinica, 37(7), 865–872. https://doi.org/10.1038/aps.2016.5   Ketamine vs. Esketamine for Depression. (2019). Psychology Today. https://www.psychologytoday.com/us/blog/two-takes-depression/201904/ketamine-vs-esketamine-depression   Office of the Commissioner. (2019). Understanding Unapproved Use of Approved Drugs “Off Label.” U.S. Food and Drug Administration. https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label   Makin, S. (2019, April 12). Behind the Buzz: How Ketamine Changes the Depressed Patient’s Brain. Scientific American. https://www.scientificamerican.com/article/behind-the-buzz-how-ketamine-changes-the-depressed-patients-brain/   An anonymous 4chan post helped solve a 25-year-old math puzzle by Grant Currin Sci-Fi Writer Greg Egan and Anonymous Math Whiz Advance Permutation Problem | Quanta Magazine. (2018). Quanta Magazine. https://www.quantamagazine.org/sci-fi-writer-greg-egan-and-anonymous-math-whiz-advance-permutation-problem-20181105/  Superpermutations — Greg Egan. (2018). Gregegan.Net. http://www.gregegan.net/SCIENCE/Superpermutations/Superpermutations.html  Anonymous 4chan Poster, Houston, R., Pantone, J., Vatter, V. (2018). A lower bound on the length of the shortest superpattern. Posted online. https://oeis.org/A180632/a180632.pdf Subscribe to Curiosity Daily to learn something new every day with Cody Gough and Ashley Hamer. You can also listen to our podcast as part of your Alexa Flash Briefing; Amazon smart speakers users, click/tap “enable” here: https://curiosity.im/podcast-flash-briefing

Learn about how we make vaccines to fight viruses like the coronavirus, with help from Julia Schaletzky, Executive Director of the Center for Emerging and Neglected Diseases at UC Berkeley. You’ll also learn about the weird history behind why we call steak “beef” and not “cow.” Additional resources from Dr. Julia Schaletzky, Executive Director of the Henry Wheeler Center for Emerging and Neglected Diseases at University of California, Berkeley: Center for Emerging and Neglected Diseases (CEND) http://cend.globalhealth.berkeley.edu/ CEND COVID-19 Outbreak Watch http://cend.globalhealth.berkeley.edu/coronavirus-outbreak-watch/ Immunotherapy and Vaccine Research Institute (IVRI) https://ivri.berkeley.edu/ Department of Molecular & Cell Biology (MCB) faculty bio for Julia Schaletzky, PhD https://haas.berkeley.edu/biology-business/academics/faculty/ Follow @CENDUCBerkeley on Twitter https://twitter.com/CENDUCBerkeley Follow  Dr. Schaletzky’s CEND profile http://cend.globalhealth.berkeley.edu/julia-schaletzky-phd/ The Norman Conquest Is Why Steak Is "Beef" and Not "Cow" by Ashley Hamer https://curiosity.com/topics/the-norman-conquest-is-why-steak-is-beef-and-not-cow-curiosity Subscribe to Curiosity Daily to learn something new every day with Cody Gough and Ashley Hamer. You can also listen to our podcast as part of your Alexa Flash Briefing; Amazon smart speakers users, click/tap “enable” here: https://curiosity.im/podcast-flash-briefing

Did you know that infectious diseases still impact 0ver 1.5 BILLION people globally? On this episode of Finding Your Frequency, we talk about infectious diseases, hookworms in Alabama, and eliminating neglected diseases. Tune in as we talk with Ellen Agler. Ellen is the CEO of the END Fund, a private philanthropic initiative working to end five neglected tropical diseases (NTDs) affecting 1 in 5 people alive today. She is a member of the World Economic Forum’s Global Health Security Advisory Board and the Uniting to Combat Neglected Tropical Diseases Stakeholders Working Group.

This paper was originally published by Emanuel Almeida Moreira de Oliveira and Karen Luise Lang in Journal of Applied Pharmaceutical Science Vol. 8(08), pp 157-165, August, 2018 under the terms of the… The post Drug Repositioning: Concept, Classification, Methodology, and Importance in Rare/Orphans and Neglected Diseases appeared first on DrugPatentWatch - Make Better Decisions.

In the United States we are familiar with common illnesses like the cold and flu, but we only hear about many diseases from beyond our shores, like the Ebola virus, when a case unexpectedly appears here. How can we create drugs to cure these illnesses, which often affect the poorest countries first, when there is […]

The Boler-Parseghian Center for Rare and Neglected Diseases at Notre Dame University conducts both basic and translational research. It also provides undergraduate students interested in going on to medical school or biomedical research, exposure to rare disease patients and the issues they face. We spoke to Kasturi Haldar, director of the center, about its work, the scientific case for linking rare and neglected diseases, and its upcoming Rare and Neglected Disease Day Conference.

Kip Guy: Addressing Health Disparities & Neglected Diseases by Research Communications

Founder and CEO of Roivant Sciences, 31-year-old Vivek Ramaswamy, goes deep into the workings of the pharmaceutical industry. He explores questions including: Why take on Alzheimers when other big pharmaceuticals aren't? Why have there been so few changes in drug development for women's health? And why he's willing to take the financial risk of investing in drug research that fails.

Bill Gates is Co-Chair of the Bill & Melinda Gates Foundation.

This weekend on YOUR HEALTH® Adam and Cristy will be talking with Kelly Callahan, Director of the Trachoma Control Program at the Carter Center about Neglected Diseases and Global Health.  Please tune in! The show will air: WCHL 97.9FM • Saturday, January 2nd at 9 a.m. • Sunday, January 3rd at 9 a.m. and 5 p.m. • Monday, […]

https://www.einstein.yu.edu - Determined to find a treatment for children with the degenerative brain disease Niemann-Pick Type C, Steven Walkley, D.V.M., Ph.D., turned a serendipitous laboratory discovery into a successful national research collaboration with other academic institutions and the National Center for Advancing Translational Sciences' program for rare diseases (Therapeutics for Rare and Neglected Diseases). These efforts led to an NIH Phase 1 clinical trial testing cyclodextrin as a therapy for children with this disease. Dr. Walkley is a professor in the Dominick P. Purpura Department of Neuroscience and director of the Rose F. Kennedy Intellectual and Developmental Disabilities Research Center at Albert Einstein College of Medicine.

Didier Pittet discusses 'the most neglected of neglected diseases': noma, linked to an Article in the July issue.

Nathan Congdon discusses assessment of cataract surgery in resource-poor settings.

Dr George Warimwe talks about his research on Rift Valley Fever. Rift Valley Fever is a mosquito-borne virus, which affects both livestock and humans in Africa and parts of the Middle East. There is currently no licensed vaccine for use in humans. Amid fears that the virus may spread to Europe, Dr George Warimwe is working with the International Livestock Research Institute (ILRI) in Africa, and the Jenner Institute to develop a vaccine against Rift Valley Fever for both humans and livestock.

Dr George Warimwe talks about his research on Rift Valley Fever. Dr George Warimwe is working with the International Livestock Research Institute (ILRI) A Centre of Excellence in Africa, and the Jenner Institute to develop a vaccine against Rift Valley Fever in humans, that will also be useful as a vaccination against the disease in livestock.

Dr George Warimwe talks about his research on Rift Valley Fever. Rift Valley Fever is a mosquito-borne virus, which affects both livestock and humans in Africa and parts of the Middle East. There is currently no licensed vaccine for use in humans. Amid fears that the virus may spread to Europe, Dr George Warimwe is working with the International Livestock Research Institute (ILRI) in Africa, and the Jenner Institute to develop a vaccine against Rift Valley Fever for both humans and livestock.

Dr George Warimwe talks about his research on Rift Valley Fever. Dr George Warimwe is working with the International Livestock Research Institute (ILRI) A Centre of Excellence in Africa, and the Jenner Institute to develop a vaccine against Rift Valley Fever in humans, that will also be useful as a vaccination against the disease in livestock.

Video Podcast (CC)Aired date: 6/6/2012 3:00:00 PM Eastern Time

Audio PodcastAired date: 6/6/2012 3:00:00 PM Eastern Time

Panelists:     Meindert Lamers, PhD, Postdoctoral researcher, UC Berkeley     Larissa Podust, PhD, Assistant Adjunct Professor, UC San Francisco     Edgar Deu Sandoval, PhD, Postdoctoral researcher, Stanford University Judges:     Karl Handelsman, MS, MBA, Managing Director, CMEA Ventures     David Mack, PhD, Director, Alta Partners     Julia Schaletzky, PhD, Scientist, Cytokinetics Moderated by Thomas Alber, PhD, Professor, Molecular and Cell Biology, UC Berkeley

Panelists:     Meindert Lamers, PhD, Postdoctoral researcher, UC Berkeley     Larissa Podust, PhD, Assistant Adjunct Professor, UC San Francisco     Edgar Deu Sandoval, PhD, Postdoctoral researcher, Stanford University Judges:     Karl Handelsman, MS, MBA, Managing Director, CMEA Ventures     David Mack, PhD, Director, Alta Partners     Julia Schaletzky, PhD, Scientist, Cytokinetics Moderated by Thomas Alber, PhD, Professor, Molecular and Cell Biology, UC Berkeley